Michael Fossler

Michael Fossler is Vice President of Strategic Consulting at Cytel. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products. In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the FDA in 2000 and joined the Clinical Pharmacokinetics Group at Dupont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. Dr. Fossler has been with Cytel since 2022. 

Michael Fossler

Related Articles

Navigating Dose Optimization in Drug Development: Answering Questions about Project Optimus
Blog
septembre 5, 2024
Navigating Dose Optimization in Drug Development: Answering Questions about Project Optimus
Read More
FDA’s Project Optimus: Redefining Oncology Drug Dosage for Better Patient Outcomes
Blog
juillet 2, 2024
FDA’s Project Optimus: Redefining Oncology Drug Dosage for Better Patient Outcomes
Read More